Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00093548
Other study ID # CDR0000389221
Secondary ID UCLA-0302008-02
Status Withdrawn
Phase Phase 1/Phase 2
First received October 6, 2004
Last updated October 3, 2012

Study information

Verified date October 2012
Source Jonsson Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Vaccines made from DNA and a gene-modified virus may make the body build an immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of liver cancer.

PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in treating patients with stage II, stage IIIA, stage IIIB, or stage IVA liver cancer.


Description:

OBJECTIVES:

Primary

- Determine the dose-limiting toxicity and maximum tolerated dose of adjuvant vaccination comprising alpha fetoprotein (AFP) plasmid DNA and sargramostim (GM-CSF) plasmid DNA followed by AFP adenoviral vector boost in patients with HLA-A*0201-expressing stage II-IVA hepatocellular carcinoma.

Secondary

- Determine the optimal biological dose of this regimen, as defined by the generation of AFP-specific immunity, in these patients.

- Determine disease-free survival of patients treated with this regimen.

OUTLINE: This is a dose-escalation study of alpha fetoprotein (AFP) adenoviral vector boost.

Patients receive vaccination comprising AFP plasmid DNA and sargramostim (GM-CSF) plasmid DNA intramuscularly (IM) on days 1, 30, and 60 in the absence of unacceptable toxicity. Patients then receive boost immunization comprising AFP adenoviral vector IM and intradermally on day 90.

Cohorts of 3-6 patients receive escalating doses of AFP adenoviral vector boost until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed monthly for 3 months and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 3-25 patients will be accrued for this study.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Diagnosis of hepatocellular carcinoma

- Stage II-IVA disease

- No active disease after local or regional therapy (e.g., surgical resection, radiofrequency ablation, cryoablation, or ethanol injection)

- Serum alpha fetoprotein > upper limit of normal

- HLA-A*0201 positive by DNA subtyping

PATIENT CHARACTERISTICS:

Age

- Over 18

Performance status

- Karnofsky 70-100%

Life expectancy

- Not specified

Hematopoietic

- Hemoglobin > 9.0 g/dL (transfusion independent)

- Platelet count > 50,000/mm^3

- Absolute neutrophil count > 1,000/mm^3

Hepatic

- Child Pugh class A or B liver function

- Hepatitis B or C viral infection allowed

Renal

- Not specified

Cardiovascular

- No New York Heart Association class III or IV cardiac insufficiency

- No coronary artery disease

Immunologic

- HIV negative

- No other acute viral, bacterial, or fungal infection requiring therapy

- No allergy to study agents

- No history of opportunistic infection

- No high serum titer of neutralizing anti-adenoviral antibodies

- No congenital or acquired condition resulting in an inability to generate an immune response

Other

- Not pregnant

- Negative pregnancy test

- Fertile patients must use effective double-method (including a barrier method) contraception

- No other condition that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- At least 30 days since prior chemotherapy

- No concurrent cytotoxic chemotherapy

Endocrine therapy

- At least 30 days since prior steroid therapy

- No concurrent steroid therapy, including corticosteroids

Radiotherapy

- Not specified

Surgery

- See Disease Characteristics

- No prior organ allograft

Other

- At least 2 weeks since prior therapy for acute infection

- No concurrent immunosuppressive therapy

- No concurrent cyclosporine

Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
alpha fetoprotein adenoviral vector vaccine

alpha fetoprotein plasmid DNA vaccine

sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)
See also
  Status Clinical Trial Phase
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Recruiting NCT05160740 - Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer N/A
Completed NCT01906021 - Study of New Software Used During Ablations N/A
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Recruiting NCT05953337 - Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) N/A
Enrolling by invitation NCT04466124 - Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy
Not yet recruiting NCT04053231 - Hepatocarcinoma Recurrence on the Liver Study - Part2
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT03059238 - Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure Phase 3
Recruiting NCT02632188 - Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT01388101 - Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor) N/A
Completed NCT00980239 - HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver Phase 1
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Completed NCT01042041 - Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer Phase 1
Completed NCT00790569 - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking N/A
Completed NCT00543777 - Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease Phase 1/Phase 2
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A